Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Gild crawled time : 13:00 save search
Assembly Biosciences Announces Effective Date of Reverse Stock Split
Published: 2024-02-08 (Crawled : 13:00) - globenewswire.com
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.03%
H: 0.26%
C: -0.81%
ASMB | $13.64 2.33% 2.27% 11K
|
Health Technology
|
| O: 0.02%
H: 3.0%
C: -2.49%
Assembly Biosciences Provides Anticipated Development Milestones for 2024
Published: 2024-01-04 (Crawled : 13:00) - globenewswire.com
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.37%
H: 1.38%
C: 0.82%
ASMB | $13.64 2.33% 2.27% 11K
|
Health Technology
|
| O: 1.84%
H: 0.73%
C: -2.44%
Gilead Showcases Latest HIV Pipeline Progress and the Impact of Global Collaboration on Health Equity Efforts at IAS 2023
Published: 2023-07-19 (Crawled : 13:00) - biospace.com/
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.15%
H: 1.92%
C: 1.1%
health pipeline global collaboration hiv impact
Kite Announces Completion of Marketing Authorization Transfer for Yescarta® CAR T-cell Therapy in Japan
Published: 2023-06-22 (Crawled : 13:00) - biospace.com/
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.18%
H: 0.57%
C: 0.46%
yescarta japan transfer t-cell authorization therapy
Gilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera
Published: 2023-05-09 (Crawled : 13:00) - biospace.com/
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.36%
H: 1.23%
C: 0.63%
pipeline acquisition
Gilead Remains Steadfast in Support for Hepatitis C Elimination Efforts
Published: 2023-05-03 (Crawled : 13:00) - biospace.com/
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.06%
H: 0.51%
C: -1.29%
hepatitis
Kite’s Tecartus® CAR T-Cell Therapy Demonstrates Overall Survival Benefit in Three-Year Follow-up of Pivotal ZUMA-3 Trial in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Published: 2023-02-09 (Crawled : 13:00) - biospace.com/
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.19%
H: 0.9%
C: -0.35%
tecartus t-cell leukemia trial therapy
ImmunoGen Announces Clinical Collaboration with Gilead to Evaluate Pivekimab Sunirine in Combination with Magrolimab in Relapsed/Refractory Acute Myeloid Leukemia
Published: 2022-12-09 (Crawled : 13:00) - biospace.com/
IMGN | $31.23 0.03% 49M
|
Health Technology
|
| O: -0.19%
H: 0.77%
C: -0.77%
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -1.45%
collaboration leukemia acute myeloid leukemia
Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model Myriad Genetics, Inc., a leader in genetic testing and preci...
Published: 2022-12-09 (Crawled : 13:00) - biospace.com/
SXT | $69.14 1.33% 0.0% 190K
|
Distribution Services
|
| O: -0.42%
H: 0.97%
C: -0.33%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.06%
H: 2.11%
C: -0.06%
TRIB | $1.81 -3.72% -3.87% 5.7K
|
Health Technology
|
| O: -1.56%
H: 1.58%
C: -1.75%
REPL | $6.47 -7.17% -7.73% 870K
|
Health Technology
|
| O: -0.25%
H: 5.25%
C: 4.17%
MYGN F | $18.515 0.03% 0.03% 490K
|
Health Technology
|
| O: -0.67%
H: 1.39%
C: -2.69%
IMGN | $31.23 0.03% 49M
|
Health Technology
|
| O: -0.19%
H: 0.77%
C: -0.77%
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -1.45%
BNTX | $86.82 0.75% 0.75% 1.6M
|
Health Technology
|
| O: -0.05%
H: 0.75%
C: -0.83%
APM | $5.9 9.87% 8.98% 37K
|
Health Technology
|
| O: -16.14%
H: 19.24%
C: 14.67%
risk breast genetic cancer study
Jounce Therapeutics Presents INNATE Phase 1 and SELECT Clinical Trial data at the European Society of Medical Oncology Immuno-Oncology (ESMO - IO) Annual Congress
Published: 2022-12-08 (Crawled : 13:00) - globenewswire.com
JNCE | $1.88 -2.59% -1.85% 0
|
Health Technology
|
| O: 1.82%
H: 1.52%
C: -7.91%
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.09%
H: 1.98%
C: 1.82%
medical trial therapeutics phase 1
Global Cervical Cancer Treatment Market Size Expected to Reach $11 Billion By 2027
Published: 2022-10-06 (Crawled : 13:00) - prnewswire.com
ZLAB | News | $14.08 -0.99% -0.99% 470K
|
Health Technology
|
| O: 0.35%
H: 1.48%
C: -4.65%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.04%
H: 0.67%
C: -0.47%
PDSB | $2.64 -8.97% -9.85% 880K
|
Health Technology
|
| O: -0.55%
H: 6.11%
C: -0.56%
ILMN | $117.43 0.63% 0.63% 1.4M
|
Health Technology
|
| O: -0.88%
H: 1.39%
C: -1.79%
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.86%
H: 0.72%
C: 0.09%
treatment global expected cancer market
Gilead Joins First-of-its-Kind Public-Private Initiative to Improve Management of Viral Hepatitis in Vietnam and the Philippines
Published: 2022-09-22 (Crawled : 13:00) - biospace.com/
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.24%
H: 1.52%
C: 0.66%
hepatitis management
Jounce Therapeutics Reports Results from Phase 2 Randomized SELECT Trial Testing 2 Different Doses of Vopratelimab in TISvopra Biomarker-Selected Patients
Published: 2022-08-30 (Crawled : 13:00) - biospace.com/
JNCE | $1.88 -2.59% -1.85% 0
|
Health Technology
|
| O: -20.58%
H: 0.0%
C: 0.0%
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.1%
H: 0.29%
C: -0.02%
trial therapeutics results phase 2
Kronos Bio Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Lanraplenib in Combination with Gilteritinib in Acute Myeloid Leukemia
Published: 2022-08-22 (Crawled : 13:00) - biospace.com/
KRON | $0.99 -3.88% -4.04% 120K
|
Health Technology
|
| O: -1.64%
H: 1.19%
C: -4.53%
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.2%
H: 0.06%
C: -1.3%
leukemia trial acute myeloid leukemia phase 2b
Humanigen Announces Peer-Reviewed Publication in Thorax Supporting Early Treatment of Hospitalized COVID-19 Patients with Lenzilumab Guided by C-Reactive Protein
Published: 2022-07-06 (Crawled : 13:00) - biospace.com/
HGEN | $0.0361 -61.5% 120M
|
Health Technology
|
| O: 0.0%
H: 27.62%
C: 14.36%
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.72%
H: 0.41%
C: 0.18%
covid-19 treatment lenzilumab publication
Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV
Published: 2022-06-24 (Crawled : 13:00) - biospace.com/
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 1.52%
H: 0.0%
C: 0.0%
chmp hiv positive drug
Allogene, Progenity, Adaptive Phage Tout New Top Executives
Published: 2022-04-29 (Crawled : 13:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.48%
H: 0.24%
C: 0.24%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.13%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.93%
H: 0.0%
C: 0.0%
HALO M | $38.64 2.2% 2.15% 1.3M
|
Health Technology
|
| O: -2.18%
H: 1.04%
C: -3.53%
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.77%
H: 0.81%
C: -3.61%
EXEL | $22.51 0.09% 0.09% 2.3M
|
Health Technology
|
| O: 0.22%
H: 1.67%
C: -1.8%
DRRX | $0.9019 -0.89% -0.9% 110K
|
Health Technology
|
| O: -0.36%
H: 1.84%
C: -4.72%
FSD Pharma Appoints Julia Levy Award Recipient David Allan and Dr. John McGraw to Advisory Board
Published: 2022-04-21 (Crawled : 13:00) - biospace.com/
SYK | $325.43 -0.62% 0.0% 1.8M
|
Health Technology
|
| O: 1.27%
H: 0.0%
C: 0.0%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.16%
H: 0.0%
C: 0.0%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 1.59%
H: 0.0%
C: 0.0%
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.68%
H: 0.0%
C: 0.0%
HUGE | $0.6167 1.22% 29K
|
Process Industries
|
| O: 0.0%
H: 0.0%
C: 0.0%
pharma
Jounce Therapeutics to Participate in Raymond James LILRB/ILT Symposium: Deep Dive into “Myeloid Checkpoint” Therapeutics in Cancer
Published: 2022-04-20 (Crawled : 13:00) - biospace.com/
JNCE | $1.88 -2.59% -1.85% 0
|
Health Technology
|
| O: 1.85%
H: 4.2%
C: 2.17%
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 2.4%
H: 0.0%
C: 0.0%
therapeutics cancer
Kite Receives U.S. FDA Approval of New State-of-the-Art CAR T-Cell Therapy Manufacturing Facility in Maryland
Published: 2022-04-19 (Crawled : 13:00) - biospace.com/
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.18%
H: 0.0%
C: 0.0%
fda t-cell approval therapy
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.